-
Mashup Score: 1Brentuximab vedotin and CHP for PTCL: upcoming Phase II trial - 3 year(s) ago
Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH discusses the upcoming Phase II trial (NCT04569032) assessing brentuximab vedotin…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The TOTAL trial: brentuximab vedotin + gemcitabine in R/R peripheral T-cell lymphoma - 3 year(s) ago
Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, presents the results of the Phase II study (NCT03496779) investigating the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial - 3 year(s) ago
David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the 5-year update of ECHELON-1 (NCT01712490), a Phase…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Although the trial did not meet the prespecified activity criteria, brentuximab vedotin plus nivolumab is active in older patients with previously untreated Hodgkin lymphoma with comorbidities. The regimen was also well tolerated in the majority of patients in this older population. Future trials should be based on optimising the dose and schedule, perhaps combined with other targeted agents that…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet
Brentiximab vedotin and CHP for peripheral T-cell #Lymphoma w/ @DeepJagMD of @caseccc Video interview here 👉https://t.co/0SKhbc7tws👈 @ASH_hematology #ASH20 #HemOnc #lysm #brentuximab #CTSM #ImmunoOnc #TrialUpdate